Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Trans-resveratrol oral - Jupiter Neurosciences

Next Previous
Drug Profile

Trans-resveratrol oral - Jupiter Neurosciences

Alternative Names: JNS 101; JNS 102; JNS 107; JNS 108; JNS 109; JNS 110; JNS 120; JOT-101; JOTROL​; JSN-115

Latest Information Update: 28 Apr 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Jupiter Orphan Therapeutics
  • Developer Jupiter Neurosciences; Mayo Clinic; Murdoch Childrens Research Institute; Universidade de Coimbra
  • Class Antidementias; Antineoplastics; Antiparkinsonians; Antithrombotics; Cardiovascular therapies; Neuroprotectants; Nonsteroidal anti-inflammatories; Phenols; Small molecules; Stilbenes; Vasodilators
  • Mechanism of Action Angiogenesis inhibitors; Antioxidants; Platelet aggregation inhibitors; Ribonucleotide reductase inhibitors; SIRT1 protein stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Friedreich's ataxia
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Alzheimer's disease; Friedreich's ataxia; Mild cognitive impairment
  • Preclinical Amyotrophic lateral sclerosis; COVID 2019 infections; Parkinson's disease; Traumatic brain injuries
  • No development reported MELAS syndrome; Mucopolysaccharidosis I
  • Discontinued Pancreatic cancer; Spinocerebellar degeneration

Most Recent Events

  • 28 Apr 2025 No recent reports of development identified for phase-I development in MELAS-syndrome in USA (PO)
  • 28 Apr 2025 No recent reports of development identified for phase-I development in Mucopolysaccharidosis-I in USA (PO, Capsule)
  • 08 Apr 2025 Jupiter Neurosciences plans to Launch of consumer longevity products in third quarter 2025

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top